Fingerprint
Dive into the research topics of 'Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies
Stephen M. Ansell, Ian Flinn, Matthew H. Taylor, Branimir I. Sikic, Joshua Brody, John Nemunaitis, Andrew Feldman, Thomas R. Hawthorne, Tracey Rawls, Tibor Keler, Michael J. Yellin
Research output: Contribution to journal › Article › peer-review
46
Scopus
citations